pharma · Advanced Non Small Cell Lung Cancer
Yongchang Zhang drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Yongchang Zhang drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Antineoplastic and immunomodulating agents (L01) compound in Yongchang Zhang's portfolio. Molecular target: Programmed cell death protein 1.